Table 1 Basic characteristics of the study population divided by recurrence <1 year vs no recurrence or later than 1 year
Total inclusion n =173 | |||
|---|---|---|---|
Variable | Recurrence <1 year ( n =82) | No recurrence or recurrence >1 year ( n =91) | P -value |
Age (years, median (range)) | 63 (36–81) | 65 (37–84) | 0.26 |
Gender (male) | 52 (63%) | 59 (65%) | 0.85 |
Liver metastases | |||
Number of tumours (median (range))a | 2 (1–10) | 1 (1–8) | 0.04 |
Size largest tumour (cm, median (range))a | 2.8 (0.2–18) | 2.6 (0.2–10) | 0.24 |
Bilobar distribution | 27 (33%) | 28 (31%) | 0.76 |
Time to resection | |||
Synchronous | 27 (33%) | 25 (28%) | 0.02 |
Metachronous | 34 (42%) | 55 (60%) | |
Recurrence | 21 (25%) | 11 (12%) | |
Clinical risk score a | |||
0–2 | 46 (60%) | 69 (79%) | <0.01 |
3–5 | 31 (40%) | 18 (21%) | |
Preoperative chemotherapy | 41 (50%) | 39 (43%) | 0.35 |
Primary tumour | |||
Site primary tumoura | |||
Colon | 59 (72%) | 66 (73%) | 0.84 |
Rectum | 23 (28%) | 24 (27%) | |
Tumour-stage primary tumoura | |||
0–2 | 11 (14%) | 12 (13%) | 0.94 |
3–4 | 69 (86%) | 78 (87%) | |
Lymph node primary tumoura | |||
Positive | 49 (60%) | 45 (50%) | 0.17 |
Negative | 32 (40%) | 45 (50%) | |
